A Non-inferiority Randomized Controlled Trial Comparing the Rehabilitation Effects of Zhenzhongdan and Eszopiclone in Elderly Patients with Insomnia Disorder of the Heart–Kidney Disharmony Pattern

INTERVENTION: Zhenzhongdan:It was administered orally twice daily, 30 minutes after lunch and 1 hour before bedtime, 7 days per week for 4 weeks.;Eszopiclone:Eszopiclone was administered orally once daily at bedtime, at a dose of 3 mg, 7 days per week for 4 weeks.; CONDITION: 7A0Z Insomnia Disorder PRIMARY OUTCOME: Pittsburgh Sleep Quality Index; SECONDARY OUTCOME: Epworth Sleepiness Scale;Fatigue Severity Scale;Hamilton Anxiety Rating Scale;Hamilton Depression Rating Scale;Montreal Cognitive Assessment;Trail Making Test Part B;Stroop Color‐Word Test;Auditory Vocabulary Learning Test;Digit n‐back task;Objective Sleep Parameters;Physical activity level;Traditional Chinese Medicine (TCM) Syndrome Efficacy Indicators;Magnetic Resonance Imaging; INCLUSION CRITERIA: 1)Aged 60–80 years; 2)Meeting the diagnostic criteria for primary chronic insomnia according to the International Classification of Sleep Disorders, Third Edition (Text Revision) (ICSD‐3‐TR); 3)Meeting the diagnostic criteria for insomnia with heart–kidney disharmony according to traditional Chinese medicine; 4)Pittsburgh Sleep Quality Inde X(PSQI) score = 6 before treatment; 5)No treatment with sedative–hypnotics, antidepressants, antipsychotics, or sedative traditional Chinese medicines within 1 month prior to enrollment; 6)Right‐handed; 7)Able to understand and cooperate with the study procedures, and voluntarily provide written informed consent.